|
|
| | BAY 80-6946 (Copanlisib) Basic information |
| Product Name: | BAY 80-6946 (Copanlisib) | | Synonyms: | 2-Amino-N-[2,3-dihydro-7-methoxy-8-[3-(4-morpholinyl)propoxy]imidazo[1,2-c]quinazolin-5-yl]-5-pyrimidinecarboxamide;5-Pyrimidinecarboxamide, 2-amino-N-[2,3-dihydro-7-methoxy-8-[3-(4-morpholinyl)propoxy]imidazo[1,2-c]quinazolin-5-yl]-;Copanlisib(BAY80-6946);BAY 80-6946 (Copanlisib);7-methoxy-8-(3-morpholinopropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-amine;Aliqopa);BAY 80-6946 (Copanlisib) USP/EP/BP;Copanlisib free base | | CAS: | 1032568-63-0 | | MF: | C23H28N8O4 | | MW: | 480.52 | | EINECS: | | | Product Categories: | Inhibitors;Akt;mTOR;PI3K;PI3K/Akt/mTOR | | Mol File: | 1032568-63-0.mol |  |
| | BAY 80-6946 (Copanlisib) Chemical Properties |
| density | 1.51 | | storage temp. | Store at -20°C | | solubility | insoluble in DMSO; insoluble in H2O; insoluble in EtOH | | form | solid | | pka | 8.42±0.20(Predicted) |
| | BAY 80-6946 (Copanlisib) Usage And Synthesis |
| Uses | BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models. | | Definition | ChEBI: Copanlisib is an imidazoquinazoline that is 2,3-dihydroimidazo[1,2-c]quinazoline substituted by (2-aminopyrimidine-5-carbonyl)amino, methoxy, and 3-(morpholin-4-yl)propoxy groups at positions 5, 7 and 8, respectively. It is a intravenous pan-class I PI3K inhibitor used for the treatment of relapsed follicular lymphoma in patients who have received at least 2 prior systemic therapies. It has a role as an EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor, an antineoplastic agent and an apoptosis inducer. It is a member of morpholines, an aromatic ether, a diether, a tertiary amino compound, a secondary carboxamide, a pyrimidinecarboxamide, an aminopyrimidine and an imidazoquinazoline. |
| | BAY 80-6946 (Copanlisib) Preparation Products And Raw materials |
|